Dinactin: A New Antitumor Antibiotic with Cell Cycle Progression and Cancer Stemness Inhibiting Activities in Lung Cancer

Dinactin: A New Antitumor Antibiotic with Cell Cycle Progression and Cancer Stemness Inhibiting Activities in Lung Cancer

Lung cancer, especially non-small cell lung cancer (NSCLC), is one of the most complex diseases, despite the existence of effective treatments such as chemotherapy and immunotherapy. Since cancer stem cells (CSCs) are responsible for chemo- and radio-resistance, metastasis, and cancer recurrence, fi...

Full description

Bibliographic Details
Main Authors: Anchalee Rawangkan, Pattama Wongsirisin, Grissana Pook-In, Achiraya Siriphap, Atchariya Yosboonruang, Anong Kiddee, Jureeporn Chuerduangphui, Nanthawan Reukngam, Acharaporn Duangjai, Surasak Saokaew, Ratsada Praphasawat
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Antibiotics
Subjects:
antitumor antibiotic
cell cycle arrest
CSC
dinactin
NSCLC
stemness
Online Access:https://www.mdpi.com/2079-6382/11/12/1845

Internet

https://www.mdpi.com/2079-6382/11/12/1845

Similar Items